Free shipping on all orders over $ 500

Veltuzumab

Cat. No. M25252

All AbMole products are for research use only, cannot be used for human consumption.

Veltuzumab Structure
Synonym:

IMMU-106 hA20

Price and Availability

For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.


Quality Control & Documentation
Biological Activity

Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL).

Chemical Information
CAS Number 728917-18-8
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
References

[1] Ghid Amhaz, et al. Leuk Res Rep. Immunotherapy in indolent Non-Hodgkin's Lymphoma

[2] Celine Kaegi, et al. Front Immunol. Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders

[3] Kenneth F Baker, et al. Ann Rheum Dis. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?

Related CD20 Products
Obinutuzumab

Obinutuzumab (GA101) is a fully humanized monoclonal antibody that binds to an epitope on CD20.

Ofatumumab

Ofatumumab is a humanised anti-CD20 monoclonal antibody, which appears to inhibit early-stage B lymphocyte activation.

Rituximab

Rituximab is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM, MW: 143.86 KD.

Glofitamab

Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell lymphoma.

Ripertamab

Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL).

  Catalog
Abmole Inhibitor Catalog




Keywords: Veltuzumab, IMMU-106 hA20 supplier, CD20, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.